Intermittent Montelukast Compared to Placebo in Children Wheeze

A study compared effectiveness of intermittent montelukast with placebo in reducing wheezing episodes in 1358 children aged 10 months to 5 years and whether genotype determined the patient outcome.

Study authors found that intermittent montelukast only reduced wheezing episodes in children with arachidonate 5-lipoxygenase (ALOX5) gene promoter 5/5, a gene that has previously been associated with a better response to montelukast in adults. There was no correlation with reduced wheezing episodes for children without this specific genotype. Therefore the researchers call for more research into the effects of montelukast in children with this genetic subtype.

Wheezing - Symptom Evaluation
Wheezing is a sound arising from the airways due to an obstruction or narrowing, which prevents the free flow of air.

Source-Eurekalert

Genes and Wheezing Illness Combination Make Children Susceptible to Asthma
A combination of 17q21 genotypes and HRV respiratory infections significantly increase the risk of developing asthma in children from families with a history of asthma or allergies.

Top Facts on Asthma
Asthma is a chronic respiratory disease in which your airways narrow, swell and produce extra mucus. Read Medindia’s facts on asthma.

Quiz on Middle East Respiratory Syndrome (MERS)
MERS is a viral disease that has caused grave concern in the Arabian region. Test your knowledge on MERS by taking this quiz.